Cardiology Department
- Address
- B-dul 22 Decembrie 1989 nr 76-78,, Târgu Mureş, Romania
Cardiology Department - Lipid Disorders & Cardiovascular Risk Research
The Cardiology Department specializes in advanced clinical research focused on cardiovascular health and metabolic disorders. With particular expertise in lipid metabolism and cardiovascular risk factors, the center conducts innovative therapeutic trials aimed at addressing complex lipoprotein disorders that contribute to atherosclerotic cardiovascular disease.
- Lipoprotein(a) [Lp(a)] reduction therapies and novel pharmacological interventions
- Lipid disorder management and prevention of cardiovascular events
- Evaluation of emerging cardiovascular therapeutics targeting metabolic pathways
The department's research program emphasizes precision medicine approaches to treating elevated lipoprotein(a), a significant but historically difficult-to-treat cardiovascular risk factor. Through rigorous clinical trials, the center evaluates the superiority of novel therapeutic agents in achieving meaningful Lp(a) reduction, contributing to the development of breakthrough treatments for patients with lipoprotein disorders and elevated cardiovascular risk profiles.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cardiology Department
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| J3L-MC-EZEB: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults with Elevated Lipoprotein(a) | Eli Lilly & Co. | Phase II | Not Recruiting | Feb 2023 | Oct 2024 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ly3819469 Sodium | 1 | Unknown | 2023-02-09 | 2023-02-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.